Short-term survivors with brain metastases have modest benefits from focal and systemic therapies and remain frequent despite improving treatment landscape
Within STS, KPS and number of BM are of prognostic relevance. There is benefit from local and systemic therapy to a limited extent. Shared and carefully discussed individual therapy decisions are necessary.
Authors
- Clemens Seidel (ORCID: https://orcid.org/0000-0001-8178-5089)
- Kirsten Papsdorf
- Peter Hambsch
- Sabine Klagges
- Nils Gleim (ORCID: https://orcid.org/0000-0002-0671-9003)
- Johannes Wach (ORCID: https://orcid.org/0000-0002-4680-0412)
- Alonso Barrantes‐Freer (ORCID: https://orcid.org/0000-0001-9988-4667)
- Jiřı́ Stöhr
- Thomas Kuhnt
- Nils H. Nicolay (ORCID: https://orcid.org/0000-0003-2550-1410)
- Franziska Nägler
- M. Czogalla
Institutions
- University Hospital Leipzig (DE)
- Leipzig University (DE)
Publication Details
- Journal
- Clinical and Translational Radiation Oncology
- Published
- 2025-01-10
- DOI
- https://doi.org/10.1016/j.ctro.2025.100919
- Primary Topic
- Brain Metastases and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00